Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Geertjan van Tienhoven

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2516-2263; OpenAlex author ID A5033788401. Sources: OpenAlex.

Their work

Papers
63 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
3
Collaborators
225
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 4 papers · 2016: 1 paper · 2017: 5 papers · 2018: 4 papers · 2019: 2 papers · 2020: 6 papers · 2021: 4 papers · 2022: 7 papers · 2023: 7 papers · 2024: 10 papers · 2025: 4 papers · 2026: 5 papers

Papers 50 of 63

  1. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  2. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Co-author DOI 10.1016/s1470-2045(25)00729-6↗
  3. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  4. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  5. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  6. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  7. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  8. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  9. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  10. Impact of Short-Course Palliative Radiation Therapy on Pancreatic Cancer-Related Pain: Prospective Phase 2 Nonrandomized PAINPANC Trial. Co-author DOI 10.1016/j.ijrobp.2023.08.055↗
  11. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  12. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  13. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  14. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-330480↗
  15. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  16. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  17. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  18. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  19. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  20. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Co-author DOI 10.1016/j.ejso.2022.12.011↗
  21. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. Co-author DOI 10.1016/j.hpb.2023.04.018↗
  22. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  23. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PAN… Co-author DOI 10.1186/s12885-023-10521-1↗
  24. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  25. Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation … Co-author DOI 10.1186/s13063-022-07036-8↗
  26. Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single c… Co-author DOI 10.3389/fonc.2023.1149961↗
  27. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  28. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Co-author DOI 10.1016/j.ejca.2021.10.023↗
  29. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderl… Co-author DOI 10.1097/sla.0000000000004313↗
  30. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible but Nonrandomized Pat… Last author DOI 10.1097/sla.0000000000004364↗
  31. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a na… Co-author DOI 10.1186/s12885-022-10419-4↗
  32. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARC… Co-author DOI 10.1186/s13063-022-06829-1↗
  33. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  34. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  35. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreati… Co-author DOI 10.1186/s12885-021-08031-z↗
  36. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1245/s10434-021-10276-8↗
  37. Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy? Last author DOI 10.3389/fonc.2021.744161↗
  38. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2019.11.002↗
  39. Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. Co-author DOI 10.1097/sla.0000000000003779↗
  40. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III P… Last author DOI 10.1200/jco.19.02274↗
  41. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. Co-author DOI 10.15252/embr.201948780↗
  42. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Co-author DOI 10.3389/fonc.2020.01112↗
  43. Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/biomedicines8110444↗
  44. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  45. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Co-author DOI 10.3390/cancers11070976↗
  46. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Last author DOI 10.1002/bjs.10870↗
  47. Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. Co-author DOI 10.1016/j.ijrobp.2018.04.064↗
  48. The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. Last author DOI 10.1080/02656736.2017.1401126↗
  49. Pain relief after a short course of palliative radiotherapy in pancreatic cancer, the Academic Medical Center (AMC) experience. Last author DOI 10.1080/0284186x.2017.1400692↗
  50. Dosimetric effects of anatomical changes during fractionated photon radiation therapy in pancreatic cancer patients. Co-author DOI 10.1002/acm2.12199↗

Closest collaborators

The 25 strongest of 225 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 41 shared papers, 2015–2026 · strength 5.16
  2. Johanna W. Wilmink · 36 shared papers, 2015–2026 · strength 4.59
  3. Bas Groot Koerkamp · 31 shared papers, 2017–2026 · strength 4.14
  4. Casper H.J. van Eijck · 32 shared papers, 2011–2026 · strength 4.00
  5. Hjalmar C. van Santvoort · 23 shared papers, 2017–2026 · strength 3.12
  6. Ignace H. J. T. de Hingh · 21 shared papers, 2016–2026 · strength 2.67
  7. Bert A. Bonsing · 20 shared papers, 2014–2026 · strength 2.42
  8. Izaak Quintus Molenaar · 18 shared papers, 2016–2026 · strength 2.25
  9. Eva Versteijne · 19 shared papers, 2015–2025 · strength 2.11
  10. Marjolein Y.V. Homs · 14 shared papers, 2019–2026 · strength 1.99
  11. Hanneke W.M. van Laarhoven · 15 shared papers, 2015–2026 · strength 1.72
  12. Gijs A. Patijn · 13 shared papers, 2016–2026 · strength 1.61
  13. Jacob L. van Dam · 10 shared papers, 2021–2026 · strength 1.58
  14. Quisette P. Janssen · 10 shared papers, 2019–2026 · strength 1.53
  15. Martijn Intven · 10 shared papers, 2021–2026 · strength 1.46
  16. Judith de Vos‐Geelen · 12 shared papers, 2016–2026 · strength 1.42
  17. Sebastiaan Festen · 10 shared papers, 2016–2026 · strength 1.33
  18. Joost J.M.E. Nuyttens · 11 shared papers, 2011–2025 · strength 1.29
  19. Geert Kazemier M · 9 shared papers, 2015–2026 · strength 1.19
  20. Vincent Erwin de Meijer · 8 shared papers, 2020–2026 · strength 1.15
  21. Anna M E Bruynzeel · 8 shared papers, 2015–2025 · strength 1.10
  22. Marion B.M. van der Kolk · 7 shared papers, 2016–2026 · strength 0.95
  23. Martijn W.J. Stommel · 6 shared papers, 2024–2026 · strength 0.95
  24. Lois A. Daamen · 6 shared papers, 2022–2026 · strength 0.91
  25. Iris W.J.M. van Goor · 6 shared papers, 2022–2026 · strength 0.91

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.